Figure 4: ETC-1002 treatment reduces the progression of atherosclerosis.

Apoe^−/− and Apoe^−/−/Ampkβ1^−/− (DKO) mice were fed a HFHC diet for 12 weeks with or without ETC-1002 targeted to achieve a 30 mg kg⁻¹ per day dose. (a) Sections of the aortic sinus from control and ETC-1002-treated mice were stained with haematoxylin and eosin and atherosclerotic lesion size determined; n=8 for all treatment groups except ETC-1002-treated Apoe^−/− (n=7). (b) Total cholesterol (TChol) was measured in whole aorta (n=4 for Apoe^−/− and 6 for DKO HFHC-fed mice) and (c) plasma SAA measured at the end of study (n=10). Data are expressed as mean±s.e.m. Multiple comparisons were made using an *one-way (within Apoe^−/− treatment groups) or #two-way ANOVA (between Apoe^−/− and DKO treatment groups); Bonferroni’s multiple comparisons test; *and ^#P<0.05. NS, not significant.